Sanara MedTech Q2 2021 Earnings Report
Key Takeaways
Sanara MedTech reported a record sales quarter driven by strong product sales across a wider number of facilities and geographies. The company closed on the Pixalere partnership and completed the acquisition of certain assets of Rochal Industries, LLC.
Sanara had another record sales quarter to end the first half of 2021.
Results were driven by strong product sales across a wider number of facilities and geographies.
The company continued to execute on its comprehensive wound and skin strategy by closing on the Pixalere partnership.
Subsequent to the end of the quarter, Sanara completed the acquisition of certain assets of Rochal Industries, LLC.
Sanara MedTech
Sanara MedTech
Forward Guidance
This press release contains forward-looking statements regarding anticipated benefits of the Rochal acquisition, the development of new products and expansion of the Company’s business in telehealth and wound care.
Positive Outlook
- Anticipated benefits of the Rochal acquisition
- Development of new products
- Expansion of the Company’s business in telehealth
- Expansion of the Company’s business in wound care
Challenges Ahead
- Sanara’s ability to successfully integrate the acquired business and operations of Rochal
- Sanara’s ability to retain key employees following the acquisition
- Unexpected costs or expenses that may result from the acquisition
- Uncertainties associated with the development and process for obtaining regulatory approval for new products
- The extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings